Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918692 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
A Phase 1 study of Acute Myeloid Leukemia, sponsored by Biomea Fusion.
- Active
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 14
- Study locations
NCT05918692: Active Phase 1 study of Acute Myeloid Leukemia, sponsored by Biomea Fusion.
NCT05918692 is a Phase 1 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by Biomea Fusion. The registered enrollment target is 35 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (70% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918692, a Phase 1 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Biomea Fusion.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Primary Outcome
Assessed by the NCI CTCAE version 5.0.
Conditions Studied
Interventions
- DRUG BMF-500
Study Locations (14)
California
- City of Hope National Medical Center - Duarte
- University of California, San Francisco - San Francisco
Texas
- Texas Oncology-PA USOR - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Mayo Clinic - Phoenix
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic - Jacksonville
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern Memorial Hospital - Chicago
Kentucky
- University of Kentucky - Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What the registry record for NCT05918692 still lists
NCT05918692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BMF-500 is the first listed.
NCT05918692 lists 14 locations in 12 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT05918692 about?
NCT05918692 is a clinical study titled "A Phase 1 Study of BMF-500 in Adults With Acute Leukemia". A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
What is the current status of trial NCT05918692?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2023-07-26. Estimated completion is 2026-04.
What conditions does trial NCT05918692 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT05918692?
The interventions under investigation include: BMF-500 (DRUG).
Who is sponsoring clinical trial NCT05918692?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918692 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918692's enrollment target sits among peer trials
35 192nd of 306 higher than 113 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI